Herpes zoster, commonly known as shingles, is an acutely painful condition caused by the reactivation of the varicella-zoster virus (VZV)—the same virus responsible for chickenpox. After an initial chickenpox infection, the virus lies dormant in the dorsal root ganglia of a dermatome. Upon reactivation, it manifests as characteristic vesicular blistering lesions along that specific dermatomal distribution.
Anyone who has had chickenpox is at risk for shingles. It is most frequently observed in adults aged 50 and older, immunocompromised individuals, or those with underlying health conditions. When shingles appears in younger adults, underlying immunocompromise should be considered. During an acute outbreak, the varicella-zoster virus is actively shed, meaning patients can transmit the infection to non-immune individuals.
Clinical Concept: Zoster’s characteristic blistering lesions occur unilaterally along a dermatome, usually do not cross the anatomical midline, and erupt following a distinct prodromal phase.
The clinical course of shingles typically unfolds in distinct phases:
Diagnosis is primarily clinical. If laboratory confirmation is needed, a Tzanck smear reveals giant multinucleated cells characteristic of herpesvirus infections.
Initiating oral antiviral therapy within the first 72 hours of rash onset limits lesion severity and reduces the risk of scarring and postherpetic neuralgia. Combining high-dose antivirals with systemic corticosteroids during the acute phase can accelerate pain resolution, though steroids do not speed lesion clearance.
| Therapy Type | Medications & Interventions | Clinical Rationale |
|---|---|---|
| First-Line Antivirals | Acyclovir (Zovirax®), Valacyclovir (Valtrex®), or Famciclovir (Famvir®) | Start within 72 hours of outbreak to reduce severity and PHN risk. |
| Adjunctive Anti-inflammatory | Systemic Corticosteroids | Used alongside antivirals in acute stages for faster pain relief. |
| Symptomatic Analgesia | Topical Lidocaine 5% gel, Burow’s solution, High-potency NSAIDs, or Opioids | Provides pain and pruritus relief during acute eruption. |
| Barrier Protection | Petroleum jelly (Vaseline) with a loose protective dressing | Protects lesions from clothing friction and irritation. |
Postherpetic neuralgia (PHN) is defined as persistent pain lasting at least 1 month after the rash has healed. PHN incidence increases dramatically with age—occurring in 4% of patients aged 30–50, compared to nearly 50% of adults over 80 years old. Additional risk factors include severe initial rash, intense prodromal pain, and trigeminal or brachial plexus involvement.
Established PHN pain can be refractory even to opioids. Effective management strategies include:
Vaccination is the primary strategy for preventing shingles and its sequelae:
Clinical Concept: Patients who previously received the live Zostavax vaccine should still receive the recombinant Shingrix vaccine for optimal, long-term protection. Vaccination can be administered to individuals with a history of shingles, but administration should be delayed until the acute episode completely resolves (usually 8 weeks post-onset).
1. James WD, Berger TG, Elston DM. Andrews’ Diseases of the Skin: Clinical Dermatology. 12th ed. Philadelphia, PA: Elsevier; 2016:372–376.
2. Janniger CK. Herpes zoster. Medscape.
3. McElveen WA. Postherpetic neuralgia. Medscape.
